China is becoming a popular destination for foreign cancer patients seeking CAR-T treatment, thanks to its lower costs and biotechnology innovations. The cost of the therapy is lower than in the West. Chinese regulators have recently approved nine CAR-T drugs, the most in the world, including the first approved therapy for solid tumors.